Floatz logo

Fluzoparib

BRCA1/2 Mutation or Not

Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the BRCA1/2 Mutation or Not cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Fluzoparib is also rated in:

neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
primary peritoneal carcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →